STAT Plus: The biotech scorecard for the second quarter: 18 stock-moving events to watch
RYAN PIERSE/GETTY IMAGES
The coronavirus pandemic has fundamentally disrupted the biotech industry. But the second quarter still promises to be an extremely busy one.


No hay comentarios:
Publicar un comentario